The present invention relates to biomarker panel for diagnosing CMS4 Subtype of colorectal cancer and diagnostic method using the same. Even among consensus molecular subtypes (CMSs) of colon cancer, CMS4 subtype is a group that exhibits significant changes in the expression of EMT-related genes and genes related to TGF-B signaling, angiogenesis, the activity of the complement-mediated inflammatory system, and stromal invasion, and is characterized by being the most incurable and poorly prognostic. The present invention is remarkably effective for accurately diagnosing the most difficult-to-treat and poorly prognostic types of colon cancer, and thus is expected to be widely used in the fields of medicine and health.

The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.

Disclosed is buoyant wave energy capture device, adapted to float adjacent to an upper surface of a body of water over which waves pass, and adapted to capture a portion of the radiated waves created by its own rising and falling in response to incident and/or passing environmental waves. A power take off mechanism combined with the disclosed wave energy capture device may be tuned to a specific wave frequency, and thereby optimally extract energy from a motion of a single frequency, even the wave energy capture device may be excited and/or energized by waves of any of a relatively broad range of frequencies, thereby increasing the power-generation and cost efficiencies of such devices relative to wave energy conversion devices of the prior art.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

The present invention relates to a biomarker for predicting the prognosis of colorectal cancer by using changes in expression level of NNT and/or OSBPL3, and a prognosis prediction method using same. The expression level of NNT and/or OSBPL3 is analyzed so that the prognosis of colorectal cancer patients in clinical practice can be predicted, and if the analysis is performed in combination with TNM stage, more accurate prediction can be made such that individualized and customized strategies can be designed.

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

This disclosure provides methods and compositions for detecting splice variants of the endoglin protein, enabling the accurate diagnosis of cancer. Additionally, the use of endoglin-specific antibodies enhances the detection process, offering a more precise and reliable approach to identifying cancer-related variants of endoglin.

Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.

This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.